Market News & Trends
Novo Nordisk Announces Phase 3a Results Using Emisphere’s Technology
Novo Nordisk recently announced the completion and results regarding its Pioneer 9 and Pioneer 6 Phase 3a trials, both conducted with oral semaglutide, a once-daily…
CBT Pharmaceuticals & Zhejiang Bossan Pharmaceutical Enter Collaboration & License Agreement
CBT Pharmaceuticals (CBT) and Zhejiang Bossan Pharmaceutical Co., Ltd (Bossan) recently announced they have entered into a clinical collaboration and license agreement to develop their…
Dalton Pharma Services Enters Drug Development & Manufacturing Services Agreement
Dalton Pharma Services recently announce a drug development and manufacturing services agreement with ExCellThera Inc. This agreement provides ExCellThera access to Dalton’s state-of-the-art cGMP, Health…
Edge Therapeutics Enters Into Merger Agreement With PDS Biotechnology
Edge Therapeutics, Inc. and PDS Biotechnology Corporation recently announced their respective boards of directors have approved a definitive merger agreement. The merger is expected to…
OSE Immunotherapeutics & Oncology Physician Network GERCOR Announce Initiation of Phase 2 Clinical Trial
OSE Immunotherapeutics SA recently announced that the French National Agency for Medicines and Health Products Safety (ANSM) and the French Central Ethic Committee (CPP) approved…
BrainStorm Cell Therapeutics Announces Submission of IND
BrainStorm Cell Therapeutics Inc. recently announced that it has submitted an Investigational New Drug (IND) application with the US FDA to initiate a Phase 2…
Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Clinical Trial
Tenax Therapeutics, Inc. recently announced that Stanford University School of Medicine has been activated as the first clinical research site for the company’s Phase 2…
Adial Pharmaceuticals Engages CRO to Begin Phase 3 Clinical Trials
Adial Pharmaceuticals, Inc. and Crown CRO recently announced Crown’s engagement to manage Adial’s Phase 3 clinical trial for AD04 for the treatment of alcohol use…
New Phase 1 Zika Vaccine Trial Meets Primary Endpoint
Emergent BioSolutions Inc. and Valneva SE (VLA) recently announced positive interim results for the Phase 1 study evaluating VLA1601, their vaccine candidate against the Zika virus. The…
Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA
Synthetic Biologics, Inc. recently announced it has successfully completed an End-of-Phase 2 meeting with the US FDA to discuss development of SYN-004 (ribaxamase) for the…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….